The efficacy and adverse reactions of Kangai injection combined with CTF regimen in neoadjuvant chemotherapy for breast cancer
- VernacularTitle:康艾注射液联合CTF方案在乳腺癌新辅助化疗中的疗效与不良反应研究
- Author:
Xiaoqiang TAN
1
;
Qifei CHEN
;
Xiaobo LUO
;
Xiaohui HU
Author Information
1. 上海市东方医院吉安医院肿瘤科
- Keywords:
Breast cancer;
Neoadjuvant chemotherapy;
Kang'ai;
Adverse reactions
- From:
China Modern Doctor
2018;56(13):74-77
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy and adverse reactions of Kangai injection combined with CTF chemotherapy in neoadjuvant chemotherapy of breast cancer. Methods A total of 60 women diagnosed with breast cancer who were admitted to our hospital between January 2015 and January 2017 were selected and divided into a control group and an observation group by randomized methods. The control group received a new assistant with CTF. In the chemotherapy group, the patients in the observation group were treated with Kangai injection combined with CTF neoadjuvant chemotherapy, and the clinical treatment total effective rate, gastrointestinal reaction, abnormal liver function, abnormal renal function, alopecia, thrombocytopenia and other adverse reactions occurrence in the two groups and the quality of life before and after treatment served as a basis for comparison. Results ①The total effective rate of treatment in the observation group was higher than that in the control group(P＜0. 05);②The occurrence of adverse reactions to hair loss and thrombocytopenia in the observation group was superior to the control group(P＜0. 05);③The abnormal liver function was observed in the observation group. There was no significant difference in renal function abnormalities and gastroin testinal reactions between the control group and the observation group(P＞0. 05). ④The quality of life after treatment in the observation group was superior to that in the control group(P＜0. 05);⑤There was no significant difference in the quality of life of patients before treatment between the observation group and the control group(P＞0. 05). Conclusion This study proves that the combination of Kangai injection in neoadjuvant chemotherapy of breast cancer patients is beneficial to improve the treatment effect of patients and improve the occurrence of adverse reactions such as alopecia and thrombocytopenia in patients. It is worthy of promotion as the first choice for clinical treatment.
